According to the clinical guidelines for the secondary prevention and risk reduction of CAD, several drugs are strongly recommended to improve outcomes including antiplatelet agents, β-blockers (BB), renin-angiotensin system blockers, and statin [1–2]. This evidence concerns the gene REN and coronary artery disorder.